Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Mochida out-licenses type 2 diabetes treatment candidates

Dec. 13, 2011

Gedeon Richter gains extended marketing rights for Esmya

Dec. 12, 2011

Unigene Laboratories regains worldwide rights to oral PTH program

Dec. 12, 2011

Nissan Chemical presents novel adiponectin receptor protein 1 agonists

Dec. 12, 2011

Metabolex announces results from arhalofenate/febuxostat combination study

Dec. 12, 2011

Merck & Co. discovers new PRCP inhibitors

Dec. 12, 2011

DM-199 increases C-peptide levels in animal model

Dec. 9, 2011

Novel GPR119 receptor agonists disclosed by Boehringer Ingelheim

Dec. 9, 2011

U.S. university extracts novel agents with antidiabetic potential from African shrub

Dec. 9, 2011

New diacylglycerol O-acyltransferase 1 inhibitors show potential to treat obesity and/or diabetes

Dec. 9, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...